2021
DOI: 10.1016/j.healun.2021.01.009
|View full text |Cite
|
Sign up to set email alerts
|

Mortality in patients with cardiogenic shock supported with VA ECMO: A systematic review and meta-analysis evaluating the impact of etiology on 29,289 patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
54
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 76 publications
(58 citation statements)
references
References 26 publications
3
54
1
Order By: Relevance
“…Recent international registries have reported mortality rates ranging from 38% to 61% for VA-ECMO and 45% to 74% for Impella. 5,22 24 Our study showed an overall mortality rate of 60%, with similar rates between devices. The systematic approach through protocols showed an increase in the historical survival rates and it has been proposed that CS should be treated in dedicated care centers (Level I).…”
Section: Discussionsupporting
confidence: 67%
See 2 more Smart Citations
“…Recent international registries have reported mortality rates ranging from 38% to 61% for VA-ECMO and 45% to 74% for Impella. 5,22 24 Our study showed an overall mortality rate of 60%, with similar rates between devices. The systematic approach through protocols showed an increase in the historical survival rates and it has been proposed that CS should be treated in dedicated care centers (Level I).…”
Section: Discussionsupporting
confidence: 67%
“…The mortality rate differs according to the etiology of CS in MCS support. 22 Recent data have shown that cardiac arrest (in and out-of-hospital) and AMI have the highest mortality rates, while myocarditis and post-heart transplant have the lowest. 22 In our cohort, the mortality rates also differed among all etiologies with the highest rates for PE and post-cardiotomy and the lowest for myocarditis and post-heart transplant.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…While there is evidence to suggest wide variability in mortality rates depending on the etiology of cardiogenic shock, the Extracorporeal Life Support Organization (ELSO) registry reveals only 43% of adults on VA ECMO for any cardiac reason will survive to hospital discharge; 30-day survival rates may be as low as one-fourth among the highest risk subpopulation. 2,3 While the ELSO has provided some guidance on the patient population that should be considered for VA ECMO, the decision to initiate this high-risk intervention continues to be made on a case-by-case basis. Providers must often rely on clinical judgment to predict the likelihood of in-hospital and long-term survival, frequently resulting in unfavorable mortality rates, tremendous cost, and overutilization of hospital resources.…”
Section: Introductionmentioning
confidence: 99%
“…Whether this mode of advanced heart and lung support is associated with a mortality benefit in CS remains unknown however, though proponents believe that it may. 14,15 The field of CS desperately needs randomized controlled trials to examine these newer circulatory support strategies and guide their use. Three trials are ongoing in Europe involving CS and these may finally provide guidance in this regard.…”
mentioning
confidence: 99%